Literature DB >> 24512487

Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice.

Daphne R Pringle1, Vasily V Vasko, Lianbo Yu, Parmeet K Manchanda, Audrey A Lee, Xiaoli Zhang, Jessica M Kirschner, Albert F Parlow, Motoyasu Saji, David Jarjoura, Matthew D Ringel, Krista M D La Perle, Lawrence S Kirschner.   

Abstract

CONTEXT: Thyroid cancer is the most common form of endocrine cancer, and it is a disease whose incidence is rapidly rising. Well-differentiated epithelial thyroid cancer can be divided into papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). Although FTC is less common, patients with this condition have more frequent metastasis and a poorer prognosis than those with PTC.
OBJECTIVE: The objective of this study was to characterize the molecular mechanisms contributing to the development and metastasis of FTC.
DESIGN: We developed and characterized mice carrying thyroid-specific double knockout of the Prkar1a and Pten tumor suppressor genes and compared signaling alterations observed in the mouse FTC to the corresponding human tumors.
SETTING: The study was conducted at an academic research laboratory. Human samples were obtained from academic hospitals. PATIENTS: Deidentified, formalin-fixed, paraffin-embedded (FFPE) samples were analyzed from 10 control thyroids, 30 PTC cases, five follicular variant PTC cases, and 10 FTC cases.
INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURES: Mouse and patient samples were analyzed for expression of activated cAMP response element binding protein, AKT, ERK, and mammalian target of rapamycin (mTOR). Murine FTCs were analyzed for differential gene expression to identify genes associated with metastatic progression.
RESULTS: Double Prkar1a-Pten thyroid knockout mice develop FTC and recapitulate the histology and metastatic phenotype of the human disease. Analysis of signaling pathways in FTC showed that both human and mouse tumors exhibited strong activation of protein kinase A and mTOR. The development of metastatic disease was associated with the overexpression of genes required for cell movement.
CONCLUSIONS: These data imply that the protein kinase A and mTOR signaling cascades are important for the development of follicular thyroid carcinogenesis and may suggest new targets for therapeutic intervention. Mouse models paralleling the development of the stages of human FTC should provide important new tools for understanding the mechanisms of FTC development and progression and for evaluating new therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24512487      PMCID: PMC4010710          DOI: 10.1210/jc.2013-3101

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

1.  cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4.

Authors:  Sara Blancquaert; Lifu Wang; Sabine Paternot; Katia Coulonval; Jacques E Dumont; Thurl E Harris; Pierre P Roger
Journal:  Mol Endocrinol       Date:  2010-05-19

2.  Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma.

Authors:  Kiminori Sugino; Koichi Ito; Mitsuji Nagahama; Wataru Kitagawa; Hiroshi Shibuya; Keiko Ohkuwa; Yukiko Yano; Takashi Uruno; Junko Akaishi; Kaori Kameyama; Kunihiko Ito
Journal:  Thyroid       Date:  2011-05-26       Impact factor: 6.568

3.  Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.

Authors:  Samantha K McCarty; Motoyasu Saji; Xiaoli Zhang; David Jarjoura; Alfredo Fusco; Vasyl V Vasko; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2010-10-29       Impact factor: 5.678

4.  Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

Authors:  David J Mulholland; Linh M Tran; Yunfeng Li; Houjian Cai; Ashkan Morim; Shunyou Wang; Seema Plaisier; Isla P Garraway; Jiaoti Huang; Thomas G Graeber; Hong Wu
Journal:  Cancer Cell       Date:  2011-05-27       Impact factor: 31.743

Review 5.  Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.

Authors:  Chrisostomi Gialeli; Achilleas D Theocharis; Nikos K Karamanos
Journal:  FEBS J       Date:  2010-11-19       Impact factor: 5.542

6.  Pten in stromal fibroblasts suppresses mammary epithelial tumours.

Authors:  Anthony J Trimboli; Carmen Z Cantemir-Stone; Fu Li; Julie A Wallace; Anand Merchant; Nicholas Creasap; John C Thompson; Enrico Caserta; Hui Wang; Jean-Leon Chong; Shan Naidu; Guo Wei; Sudarshana M Sharma; Julie A Stephens; Soledad A Fernandez; Metin N Gurcan; Michael B Weinstein; Sanford H Barsky; Lisa Yee; Thomas J Rosol; Paul C Stromberg; Michael L Robinson; Francois Pepin; Michael Hallett; Morag Park; Michael C Ostrowski; Gustavo Leone
Journal:  Nature       Date:  2009-10-22       Impact factor: 49.962

7.  Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females.

Authors:  V G Antico-Arciuch; M Dima; X-H Liao; S Refetoff; A Di Cristofano
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

8.  Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.

Authors:  Aime T Franco; Roberta Malaguarnera; Samuel Refetoff; Xiao-Hui Liao; Emma Lundsmith; Shioko Kimura; Catrin Pritchard; Richard Marais; Terry F Davies; Lee S Weinstein; Min Chen; Neal Rosen; Ronald Ghossein; Jeffrey A Knauf; James A Fagin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

9.  cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity.

Authors:  Jianling Xie; Godwin A Ponuwei; Claire E Moore; Gary B Willars; Andrew R Tee; Terence P Herbert
Journal:  Cell Signal       Date:  2011-07-06       Impact factor: 4.315

10.  Isoform-specific targeting of PKA to multivesicular bodies.

Authors:  Michele E Day; Guido M Gaietta; Mira Sastri; Antonius Koller; Mason R Mackey; John D Scott; Guy A Perkins; Mark H Ellisman; Susan S Taylor
Journal:  J Cell Biol       Date:  2011-04-18       Impact factor: 10.539

View more
  16 in total

1.  GLIS3 is indispensable for TSH/TSHR-dependent thyroid hormone biosynthesis and follicular cell proliferation.

Authors:  Hong Soon Kang; Dhirendra Kumar; Grace Liao; Kristin Lichti-Kaiser; Kevin Gerrish; Xiao-Hui Liao; Samuel Refetoff; Raja Jothi; Anton M Jetten
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

2.  mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD).

Authors:  Cyrille de Joussineau; Isabelle Sahut-Barnola; Frédérique Tissier; Typhanie Dumontet; Coralie Drelon; Marie Batisse-Lignier; Igor Tauveron; Jean-Christophe Pointud; Anne-Marie Lefrançois-Martinez; Constantine A Stratakis; Jérôme Bertherat; Pierre Val; Antoine Martinez
Journal:  Hum Mol Genet       Date:  2014-05-27       Impact factor: 6.150

Review 3.  Modulation of sodium iodide symporter in thyroid cancer.

Authors:  Aparna Lakshmanan; Daniel Scarberry; Daniel H Shen; Sissy M Jhiang
Journal:  Horm Cancer       Date:  2014-09-19       Impact factor: 3.869

4.  Elevated aggressive behavior in male mice with thyroid-specific Prkar1a and global Epac1 gene deletion.

Authors:  Kathryn L G Russart; Danielle Huk; Randy J Nelson; Lawrence S Kirschner
Journal:  Horm Behav       Date:  2018-01-03       Impact factor: 3.587

5.  Sdhd ablation promotes thyroid tumorigenesis by inducing a stem-like phenotype.

Authors:  Amruta Ashtekar; Danielle Huk; Alexa Magner; Krista La Perle; Xiaoli Zhang; José I Piruat; José López-Barneo; Sissy M Jhiang; Lawrence S Kirschner
Journal:  Endocr Relat Cancer       Date:  2017-09-19       Impact factor: 5.678

Review 6.  Mouse models of thyroid cancer: A 2015 update.

Authors:  Lawrence S Kirschner; Zahida Qamri; Suresh Kari; Amruta Ashtekar
Journal:  Mol Cell Endocrinol       Date:  2015-06-27       Impact factor: 4.102

7.  In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.

Authors:  Chen Li Chew; Andrea Lunardi; Federico Gulluni; Daniel T Ruan; Ming Chen; Leonardo Salmena; Michiya Nishino; Antonella Papa; Christopher Ng; Jacqueline Fung; John G Clohessy; Junko Sasaki; Takehiko Sasaki; Roderick T Bronson; Emilio Hirsch; Pier Paolo Pandolfi
Journal:  Cancer Discov       Date:  2015-04-16       Impact factor: 39.397

8.  Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.

Authors:  Devora Champa; Marika A Russo; Xiao-Hui Liao; Samuel Refetoff; Ronald A Ghossein; Antonio Di Cristofano
Journal:  Endocr Relat Cancer       Date:  2014-07-10       Impact factor: 5.678

9.  Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma.

Authors:  Kevin M Riggle; Kimberly J Riehle; Heidi L Kenerson; Rigney Turnham; Miwako K Homma; Machiko Kazami; Bret Samelson; Renay Bauer; G Stanley McKnight; John D Scott; Raymond S Yeung
Journal:  Pediatr Res       Date:  2016-03-08       Impact factor: 3.756

10.  Alterations in Sod2-Induced Oxidative Stress Affect Endocrine Cancer Progression.

Authors:  Amruta Ashtekar; Danielle Huk; Alexa Magner; Krista M D La Perle; Laura Boucai; Lawrence S Kirschner
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.